Private equity firm Advent International on Friday announced the completion of its majority acquisition of Hyderabad-based listed contract development and manufacturing organisation (CDMO) Suven Pharma.Advent acquired 50.1% stake in Suven at an agreed price of Rs 495/share in December last year a firm promoted Venkat Jasti and his family members for Rs 6,313 crore paying ₹495 per share.Enhance Your Healthcare Expertise with High-Impact CoursesOffering CollegeCourseWebsiteIndian School of BusinessISB Healthcare ManagementVisitIIM KozhikodeIIMK Healthcare Management & Analytics ProgrammeVisitAdvent will also launch an open offer for an additional 26% of the company, taking the potential investment to Rs 9589 crore, one of the biggest in the Indian CDMO sector.The government early this month cleared the acquisition.The private equity firm on Friday has also announced the new Board of directors and management team for Suven Pharma.Suven Pharma will be led by a management team comprising Annaswamy Vaidheesh, executive chairman, V Prasada Raju, managing director and Sudhir Kumar Singh, chief executive officer to drive Suven Pharma's global growth as it aims to become a top CDMO player.Annaswamy Vaidheesh, a pharmaceutical veteran with over 35 years of experience, including as MD of GSK India, and earlier was with J&J Asia Pacific in senior regional leadership positions.Prasada Raju, has over 29 years of experience in the pharmaceutical industry, with leadership roles at Cohance Life Sciences, Granules India Ltd.

私募股权公司Advent International周五宣布完成大部分收购基于海得拉巴的上市合同开发和制造组织（CDMO）Suven Pharma。Advent去年12月以495卢比/股份的协议价格收购了Suven 50.1%的股份。一家公司促销Venkat Jasti及其家人为6313卢比付费₹495人。通过高影响力的课程增强您的医疗保健专业知识提供大学课程网站印度商学院医疗保健管理Visitiim KozhikodeiimkHealthcare管理和分析计划VisitaDVENT还将为另外26%的公司推出公开报价，并对Rs 9589 crore进行潜在投资，Rs 9589 crore是其中之一印度CDMO部门。本月初，政府批准了此次收购。周五，私募股权公司还宣布了Suven Pharma的新董事会和管理团队.Suven Pharma将由一个管理团队领导，该团队由执行主席Annaswamy Vaidheesh，总经理V Prasada Raju和首席执行官Sudhir Kumar Singh组成。推动Suven Pharma的全球增长，因为它旨在成为CDMO的顶级参与者。Annaswamy Vaidheesh是一位拥有35年以上经验的制药退伍军人，包括葛兰素史克印度医学博士，此前曾在J＆J亚太地区担任高级区域领导职位。Prasada Raju拥有29年制药行业经验，在Cohance Life Sciences，Granules India Ltd.担任领导职务。

and Dr Reddy's Laboratories. Dr Sudhir Kumar Singh, a reputed industry veteran who was the ex-COO at Aragen Life Sciences for more than 10 years, joins as the CEO of Suven Pharma.“We are delighted to enter the value creation phase of our journey with the appointment o.

和雷迪博士的实验室。Sudhir Kumar Singh博士是一位知名的行业退伍军人，曾在Aragen Life Sciences担任首席执行官超过10年，并担任Suven Pharma的首席执行官。“我们很高兴与o.一起进入我们旅程的价值创造阶段。